

## COMPOUNDS REGULATING CELLULAR PRION PROTEIN ACTIVITY

**The patent** stems from the collaborative work of a team of researchers with established expertise in neurobiology and medicinal chemistry. The patent covers in particular compounds inhibiting the activity of the cellular prion protein, a membrane glycoprotein involved in neurodegenerative diseases such as prion disease, Alzheimer's Diseases, Parkinson's Disease and Multiple Sclerosis . The project is ready to move to lead optimization phase.

### OPPORTUNITY

The different classes of compounds are described in priority filing IT102021000013244  
Biotech and pharma companies, as well as investors (venture capital) interested in learning more about the patent can contact Fondazione Telethon Business Development Office by October 10<sup>th</sup>, 2021 at the following address: [tto@telethon.it](mailto:tto@telethon.it)

### References:

- Biasini, et al. **Prion protein at the crossroads of physiology and disease.** Trends Neurosci **35**, 92-103, doi:10.1016/j.tins.2011.10.002 (2012).